Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment